PE20130158A1 - Inhibidores no nucleosidicos de la transcriptasa inversa - Google Patents

Inhibidores no nucleosidicos de la transcriptasa inversa

Info

Publication number
PE20130158A1
PE20130158A1 PE2012001823A PE2012001823A PE20130158A1 PE 20130158 A1 PE20130158 A1 PE 20130158A1 PE 2012001823 A PE2012001823 A PE 2012001823A PE 2012001823 A PE2012001823 A PE 2012001823A PE 20130158 A1 PE20130158 A1 PE 20130158A1
Authority
PE
Peru
Prior art keywords
oxo
methyl
triazol
dihydro
chloro
Prior art date
Application number
PE2012001823A
Other languages
English (en)
Spanish (es)
Inventor
Jason Burch
Bernard Cote
Natalie Nguyen
Chun Sing Li
Miguel St-Onge
Danny Gauvreau
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130158(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of PE20130158A1 publication Critical patent/PE20130158A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2012001823A 2010-03-30 2011-03-28 Inhibidores no nucleosidicos de la transcriptasa inversa PE20130158A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US32157310P 2010-04-07 2010-04-07

Publications (1)

Publication Number Publication Date
PE20130158A1 true PE20130158A1 (es) 2013-02-28

Family

ID=44710363

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001823A PE20130158A1 (es) 2010-03-30 2011-03-28 Inhibidores no nucleosidicos de la transcriptasa inversa

Country Status (44)

Country Link
US (2) US8486975B2 (enExample)
EP (2) EP2924034B1 (enExample)
JP (2) JP5281718B2 (enExample)
KR (1) KR101421861B1 (enExample)
CN (1) CN102971308B (enExample)
AR (1) AR080859A1 (enExample)
AU (1) AU2011235568B2 (enExample)
BR (1) BR112012024691B1 (enExample)
CA (1) CA2794377C (enExample)
CL (1) CL2012002744A1 (enExample)
CO (1) CO6630126A2 (enExample)
CR (1) CR20120503A (enExample)
CY (3) CY1118774T1 (enExample)
DK (2) DK2924034T3 (enExample)
DO (1) DOP2012000256A (enExample)
EA (1) EA024804B1 (enExample)
EC (1) ECSP12012201A (enExample)
ES (2) ES2609636T3 (enExample)
FI (1) FIC20190021I1 (enExample)
GE (1) GEP20156368B (enExample)
HN (1) HN2012002039A (enExample)
HR (2) HRP20150427T1 (enExample)
HU (4) HUE025336T2 (enExample)
IL (2) IL222030A (enExample)
LT (3) LT2924034T (enExample)
LU (2) LUC00114I2 (enExample)
MA (1) MA34170B1 (enExample)
ME (2) ME02181B (enExample)
MX (1) MX2012011379A (enExample)
MY (1) MY163979A (enExample)
NI (1) NI201200146A (enExample)
NL (1) NL300980I2 (enExample)
NO (2) NO2019018I1 (enExample)
NZ (1) NZ602670A (enExample)
PE (1) PE20130158A1 (enExample)
PH (1) PH12012501923A1 (enExample)
PL (2) PL2552902T3 (enExample)
PT (2) PT2924034T (enExample)
RS (2) RS55505B1 (enExample)
SG (1) SG184347A1 (enExample)
SI (2) SI2924034T1 (enExample)
TN (1) TN2012000455A1 (enExample)
TW (1) TWI458719B (enExample)
WO (1) WO2011120133A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34170B1 (fr) * 2010-03-30 2013-04-03 Merck Canada Inc Inhibiteurs de transcriptase inverse non nucléosidiques
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
CN109384765A (zh) * 2012-09-26 2019-02-26 默沙东公司 逆转录酶抑制剂的晶型
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP2928472B1 (en) * 2012-12-05 2018-05-02 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
BR112016011605A8 (pt) * 2013-11-22 2023-04-25 Merck Sharp & Dohme Composição de um inibidor de transcriptase reversa não nucleosídeo
ES2977643T3 (es) * 2013-12-04 2024-08-28 Merck Sharp & Dohme Llc Proceso para fabricar inhibidores de la transcriptasa inversa
CN106456639B (zh) * 2014-04-01 2019-05-10 默沙东公司 Hiv逆转录酶抑制剂的前药
US10301624B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Targeting human satellite II (HSATII)
HUE056978T2 (hu) 2015-12-02 2022-04-28 Merck Sharp & Dohme Doravirint, tenofovir-dizoproxil-fumarátot és lamivudint tartalmazó gyógyszerészeti kompozíciók
US11077050B2 (en) 2017-03-24 2021-08-03 Merck Sharp & Dohme Corp. Formulation for parenteral administration
BR112019021918A2 (pt) 2017-04-18 2020-05-26 Cipla Limited Terapia de combinação para uso no tratamento de infecções retroviriais
EP3749330A4 (en) 2018-02-06 2021-11-17 The General Hospital Corporation REPEATED PATTERN RNA USED AS BIOMARKERS OF TUMOR IMMUNE RESPONSE
EP3823632B1 (en) * 2018-07-17 2025-10-29 Merck Sharp & Dohme LLC Efda in combination with doravirine for use in treating f227c mutated hiv infections
CN113423695A (zh) 2018-12-18 2021-09-21 默沙东公司 作为针对hiv感染细胞的选择性细胞毒剂的嘧啶酮衍生物
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法
CN116903590A (zh) * 2023-06-06 2023-10-20 延边大学 一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN120157613A (zh) * 2023-12-15 2025-06-17 山东诚创蓝海医药科技有限公司 多拉韦林中间体及其应用和合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
MXPA05010081A (es) 2003-03-24 2005-11-23 Hoffmann La Roche Bencil-piridazinonas como inhibidores de transcriptasa inversa.
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
AU2005235692B2 (en) 2004-04-23 2011-11-10 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
EP1831157A2 (en) 2004-12-22 2007-09-12 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
ES2320042T3 (es) 2005-10-19 2009-05-18 F. Hoffmann-La Roche Ag Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ.ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドnnrt阻害剤
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
RU2010125220A (ru) 2007-11-20 2011-12-27 Мерк Шарп Энд Домэ Корп. (Us) Ненуклеозидные ингибиторы обратной транскриптазы
MA34170B1 (fr) * 2010-03-30 2013-04-03 Merck Canada Inc Inhibiteurs de transcriptase inverse non nucléosidiques

Also Published As

Publication number Publication date
LTPA2019506I1 (lt) 2019-04-25
TN2012000455A1 (en) 2014-01-30
SI2924034T1 (sl) 2017-05-31
DK2552902T3 (en) 2015-06-15
JP2013209405A (ja) 2013-10-10
ME02181B (me) 2015-10-20
LTPA2019507I1 (lt) 2019-04-25
HN2012002039A (es) 2015-08-24
HK1209121A1 (en) 2016-03-24
LUC00114I2 (enExample) 2020-07-10
MY163979A (en) 2017-11-15
ECSP12012201A (es) 2012-10-30
EA024804B1 (ru) 2016-10-31
HUS1900021I1 (hu) 2019-05-28
EA201290976A1 (ru) 2013-03-29
HUS1900022I1 (hu) 2019-05-28
MX2012011379A (es) 2012-11-30
CA2794377A1 (en) 2011-10-06
ES2536295T3 (es) 2015-05-22
LUC00113I9 (enExample) 2024-06-07
AU2011235568B2 (en) 2013-09-12
IL233334A0 (en) 2014-09-01
KR20120128703A (ko) 2012-11-27
CY2019026I2 (el) 2020-05-29
CY2019025I2 (el) 2019-11-27
CR20120503A (es) 2013-01-09
NO2019018I1 (no) 2019-04-24
EP2924034A1 (en) 2015-09-30
MA34170B1 (fr) 2013-04-03
CN102971308A (zh) 2013-03-13
TW201139409A (en) 2011-11-16
RS55505B1 (sr) 2017-05-31
NO2019019I1 (no) 2019-04-24
LUC00113I2 (enExample) 2024-05-22
NL300980I2 (nl) 2021-06-17
PT2552902E (pt) 2015-06-02
PT2924034T (pt) 2017-01-06
LTC2924034I2 (lt) 2020-10-12
CY1118774T1 (el) 2017-07-12
GEP20156368B (en) 2015-09-25
IL233334A (en) 2015-09-24
HRP20150427T1 (hr) 2015-07-03
HUE031785T2 (en) 2017-08-28
US8486975B2 (en) 2013-07-16
EP2552902A1 (en) 2013-02-06
CO6630126A2 (es) 2013-03-01
ME02570B (me) 2017-06-20
LTC2552902I2 (lt) 2019-12-10
RS54017B1 (sr) 2015-10-30
EP2552902B1 (en) 2015-03-11
JP5886790B2 (ja) 2016-03-16
DK2924034T3 (en) 2017-02-06
PL2552902T3 (pl) 2015-10-30
HRP20161680T1 (hr) 2017-01-27
SI2552902T1 (sl) 2015-10-30
LUC00114I1 (enExample) 2019-04-17
BR112012024691A2 (pt) 2019-07-02
CA2794377C (en) 2015-06-16
CN102971308B (zh) 2015-02-04
PH12012501923A1 (en) 2013-02-04
US20130296382A1 (en) 2013-11-07
NI201200146A (es) 2013-03-18
CY2019026I1 (el) 2020-05-29
NL300980I1 (nl) 2019-04-24
JP5281718B2 (ja) 2013-09-04
AU2011235568A1 (en) 2012-11-01
EP2552902A4 (en) 2013-09-04
US20110245296A1 (en) 2011-10-06
FIC20190021I1 (fi) 2019-04-17
SG184347A1 (en) 2012-11-29
IL222030A (en) 2014-07-31
LT2924034T (lt) 2016-12-27
BR112012024691B1 (pt) 2020-11-17
HK1175471A1 (en) 2013-07-05
CL2012002744A1 (es) 2012-12-14
NZ602670A (en) 2014-09-26
DOP2012000256A (es) 2012-12-15
PL2924034T3 (pl) 2017-07-31
EP2924034B1 (en) 2016-11-02
AR080859A1 (es) 2012-05-16
ES2609636T3 (es) 2017-04-21
CY2019025I1 (el) 2019-11-27
WO2011120133A1 (en) 2011-10-06
HUE025336T2 (en) 2016-03-29
KR101421861B1 (ko) 2014-07-22
TWI458719B (zh) 2014-11-01
JP2013510800A (ja) 2013-03-28

Similar Documents

Publication Publication Date Title
PE20130158A1 (es) Inhibidores no nucleosidicos de la transcriptasa inversa
PE20091000A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20131377A1 (es) Triazina-oxadiazoles
PE20141307A1 (es) Aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2)
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20110924A1 (es) Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20070946A1 (es) COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
PE20130157A1 (es) Inhibidores de la polimerasa virica
PE20130525A1 (es) Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20161400A1 (es) Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20080927A1 (es) Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk)
PE20120691A1 (es) Derivados de n1-sulfonil-5-fluoropirimidinona
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo

Legal Events

Date Code Title Description
FG Grant, registration